Template:Meropenem: Difference between revisions
No edit summary |
|||
| Line 33: | Line 33: | ||
Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of | Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of | ||
vital cell wall components, which leads to cell death. | vital cell wall components, which leads to cell death. | ||
Resistance | |||
===Mechanism of Effectiveness=== | |||
Meropenem is bactericidal except against [[Listeria monocytogenes]] where it is bacteriostatic. It inhibits bacterial wall synthesis like other [[beta-lactam]] antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by [[beta-lactamase]]s or [[cephalosporinase]]s. Resistance generally arises due to mutations in [[penicillin binding proteins]], production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.<ref name=Mosby> {{ cite book | title=Mosby's Drug Consult 2006 | publisher= Mosby, Inc. | date= 2006 | edition= 16 ed}} </ref> Unlike [[imipenem]], it is stable to [[dehydropeptidase-1]] and can therefore be given without [[cilastatin]]. | |||
===Mechanism of Resistance=== | ===Mechanism of Resistance=== | ||
There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the | There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the | ||
| Line 43: | Line 45: | ||
===Cross-Resistance=== | ===Cross-Resistance=== | ||
Cross resistance is sometimes observed with isolates resistant to other carbapenems. | Cross resistance is sometimes observed with isolates resistant to other carbapenems. | ||
==References== | ==References== | ||
Revision as of 19:48, 19 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.[1]
Category
Carbapenem
US Brand Names
Meronem, Merrem®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages
Mechanisms of Action
Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Mechanism of Effectiveness
Meropenem is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamases or cephalosporinases. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.[2] Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.
Mechanism of Resistance
There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) causing reduced bacterial uptake, 2) reduced affinity of the target penicillin binding proteins (PBP), 3) increased expression of efflux pump components, and 4) production of antibiotic-destroying enzymes (carbapenemases, metallo-β-lactamases).
Cross-Resistance
Cross resistance is sometimes observed with isolates resistant to other carbapenems.